On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and ...

In November 2024, Skyrizi surpassed Humira as AbbVie's top seller; calls for PBM transparency and biosimilar access reforms ...

Regulatory policies influence the availability of affordable biosimilars, with varying impacts across different jurisdictions ...

The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference ...

Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by ...

Bevacizumab biosimilars have the potential to expand access and reduce costs without compromising patient outcomes in ...

The phase 3 trial (NCT04966338) found that a biosimilar ocrelizumab candidate (Xacrel) was equivalent to Ocrevus in reducing the annualized relapse rate and showed comparable safety and efficacy in ...